Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
NCT07684235 on ClinicalTrials.gov · last registry update 2026-09-03
An unusually large phase 3: 3,200 participants, more than double the 424 typical for the stage. Due to report 26 December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Percent Change in Body Weight from Baseline of the Parent Trial (20210181). Sponsors move these dates routinely; any movement since this site started watching is listed below. maridebart cafraglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Sponsor
- Amgen
- Sponsor type
- Industry
- Enrollment
- 3,200
- Started
- 2026-07-23
- Primary completion
- 2027-12-26 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Change in Body Weight from Baseline of the Parent Trial (20210181)
Conditions studied
Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the maridebart cafraglutide page for this molecule’s full trial and approval history.